Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Paraskevas Iatropoulos"'
Autor:
Marco Salvatore, Agata Polizzi, Maria Chiara De Stefano, Giovanna Floridia, Simone Baldovino, Dario Roccatello, Savino Sciascia, Elisa Menegatti, Giuseppe Remuzzi, Erica Daina, Paraskevas Iatropoulos, Bruno Bembi, Rosalia Maria Da Riol, Alessandra Ferlini, Marcella Neri, Giuseppe Novelli, Federica Sangiuolo, Francesco Brancati, Domenica Taruscio
Publikováno v:
Italian Journal of Pediatrics, Vol 46, Iss 1, Pp 1-15 (2020)
Abstract Background For a number of persons with rare diseases (RDs) a definite diagnosis remains undiscovered with relevant physical, psychological and social consequences. Undiagnosed RDs (URDs) require other than specialised clinical centres, outs
Externí odkaz:
https://doaj.org/article/59147f98fbb844a99a8ff42581d76f3a
Autor:
Rossella Piras, Matteo Breno, Elisabetta Valoti, Marta Alberti, Paraskevas Iatropoulos, Caterina Mele, Elena Bresin, Roberta Donadelli, Paola Cuccarolo, Richard J. H. Smith, Ariela Benigni, Giuseppe Remuzzi, Marina Noris
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
C3 Glomerulopathy (C3G) and Immune Complex-Mediated Membranoproliferative glomerulonephritis (IC-MPGN) are rare diseases characterized by glomerular deposition of C3 caused by dysregulation of the alternative pathway (AP) of complement. In approximat
Externí odkaz:
https://doaj.org/article/bf5651269e7640a2b06033b39950716b
Autor:
Rossella Piras, Paraskevas Iatropoulos, Elena Bresin, Marta Todeschini, Sara Gastoldi, Elisabetta Valoti, Marta Alberti, Caterina Mele, Miriam Galbusera, Paola Cuccarolo, Ariela Benigni, Giuseppe Remuzzi, Marina Noris
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal impairment and is associated with dysregulation of the alternative complement pathway on the microvascular end
Externí odkaz:
https://doaj.org/article/9875cfb92ab846349f6c1740a5af9474
Autor:
Elisabetta Valoti, Marta Alberti, Paraskevas Iatropoulos, Rossella Piras, Caterina Mele, Matteo Breno, Alessandra Cremaschi, Elena Bresin, Roberta Donadelli, Silvia Alizzi, Antonio Amoroso, Ariela Benigni, Giuseppe Remuzzi, Marina Noris
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and renal failure. It is caused by genetic or acquired defects of the complement alternative pathway. Factor H autoantibo
Externí odkaz:
https://doaj.org/article/f751e243e9194374823939f57723d157
Autor:
Roberta Donadelli, Patrizia Pulieri, Rossella Piras, Paraskevas Iatropoulos, Elisabetta Valoti, Ariela Benigni, Giuseppe Remuzzi, Marina Noris
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Membranoproliferative glomerulonephritis (MPGN) was recently classified as C3 glomerulopathies (C3G), and immune-complex (IC) mediated MPGN. Dysregulation of the complement alternative pathway, driven by acquired and/or genetic defects, plays a patho
Externí odkaz:
https://doaj.org/article/a63df53643bf4290ac01c1052646d0b3
Autor:
Evangelia Papadimou, Marina Morigi, Paraskevas Iatropoulos, Christodoulos Xinaris, Susanna Tomasoni, Valentina Benedetti, Lorena Longaretti, Cinzia Rota, Marta Todeschini, Paola Rizzo, Martino Introna, Maria Grazia de Simoni, Giuseppe Remuzzi, Michael S. Goligorsky, Ariela Benigni
Publikováno v:
Stem Cell Reports, Vol 4, Iss 4, Pp 685-698 (2015)
The application of cell-based therapies in regenerative medicine is gaining recognition. Here, we show that human bone marrow stromal cells (BMSCs), also known as bone-marrow-derived mesenchymal cells, can be reprogrammed into renal proximal tubular-
Externí odkaz:
https://doaj.org/article/4b92a72d6f82461589cc7794726f97a2
Autor:
Marta Alberti, Paola Cuccarolo, Elisabetta Valoti, Caterina Mele, Paraskevas Iatropoulos, Miriam Galbusera, Ariela Benigni, Sara Gastoldi, Marina Noris, Rossella Piras, Marta Todeschini, Giuseppe Remuzzi, Elena Bresin
Publikováno v:
Frontiers in Medicine
Frontiers in Medicine, Vol 7 (2020)
Frontiers in Medicine, Vol 7 (2020)
Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal impairment and is associated with dysregulation of the alternative complement pathway on the microvascular end
Autor:
Federica Sangiuolo, Giuseppe Remuzzi, Domenica Taruscio, Marco Salvatore, Rosalia Maria Da Riol, Erica Daina, Giuseppe Novelli, Giovanna Floridia, Marcella Neri, Paraskevas Iatropoulos, Dario Roccatello, Francesco Brancati, Elisa Menegatti, Savino Sciascia, Agata Polizzi, Maria Chiara de Stefano, Bruno Bembi, Alessandra Ferlini, Simone Baldovino
Publikováno v:
Italian Journal of Pediatrics
Italian Journal of Pediatrics, Vol 46, Iss 1, Pp 1-15 (2020)
Italian Journal of Pediatrics, Vol 46, Iss 1, Pp 1-15 (2020)
Background For a number of persons with rare diseases (RDs) a definite diagnosis remains undiscovered with relevant physical, psychological and social consequences. Undiagnosed RDs (URDs) require other than specialised clinical centres, outstanding m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd47556d94597084a89e338b0b5c279
http://hdl.handle.net/2108/256559
http://hdl.handle.net/2108/256559
Autor:
Matteo Breno, Elisabetta Valoti, Marina Noris, Alessandra Cremaschi, Paraskevas Iatropoulos, Ariela Benigni, Antonio Amoroso, Marta Alberti, Giuseppe Remuzzi, Roberta Donadelli, Caterina Mele, Rossella Piras, Silvia Alizzi, Elena Bresin
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology
Frontiers in Immunology
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and renal failure. It is caused by genetic or acquired defects of the complement alternative pathway. Factor H autoantibo
Autor:
Luca Clivio, Robert Fruscio, Chiara Romualdi, Ilaria Craparotta, Patrizia Perego, E. Ronchetti, Vittoria Fotia, Caterina Mele, Lara Paracchini, Antonella Ravaggi, Alberto Zambelli, Marco Petrillo, Sergio Marchini, Enrica Calura, Maurizio D'Incalci, Paraskevas Iatropoulos, Federica Sina, B. Chapman, M. Di Marino, Paolo Martini, Luca Beltrame, Rodolfo Milani, Marina Noris, Tommaso Grassi
Publikováno v:
Annals of Oncology. 26:1363-1371
Background The majority of patients with stage III–IV epithelial ovarian cancer (EOC) relapse after initially responding to platinum-based chemotherapy, and develop resistance. The genomic features involved in drug resistance are unknown. To unrave